Categories
Change Password!
Reset Password!
CGRP
monoclonal antibodies are safe and effectively attenuates monthly
migraine days and acute migraine-specific medication in migraine patients.
The calcitonin
gene-related peptide (CGRP) monoclonal antibodies exhibited a significant and
safe impact on monthly migraine days and associated medications usage. CGRP
monoclonal antibody is from the family of neuropeptides release from the motor
and sensory neurons. This meta-analysis was conducted to evaluate the role and
safety of this neuropeptide in providing relief from episodic migraine.
The randomized
controlled trials with associated data were searched from Web of Science, the
Cochrane Library, MEDLINE, and EMBASE till April 2018. A total of 8 trials with
2292 patients were selected. As compared to placebo, CGRP monoclonal antibodies
were observed to significantly reduce the monthly acute migraine-specific medicine
consumption and monthly migraine days from the baseline. A ≥ 50% reduction from
baseline in migraine days per month was noticed in the CGRP monoclonal
antibodies group. However, no difference was seen among the groups related to
adverse events.
As per the subgroup
analysis results, the drugs that showed remarkable positive results were
Fremanezumab, Erenumab and Galcanezumab. These findings exhibit a considerable
impact of CGRP monoclonal antibodies role to lessen the migraine days and
utilization of medication.
Neurological Sciences
The efficacy and safety of calcitonin gene-related peptide monoclonal antibody for episodic migraine: a meta-analysis.
Yuhan Zhu et al.
Comments (0)